Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:EYEGNASDAQ:KMPHNASDAQ:NTEC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$1.33-5.0%$1.46$0.77▼$14.00$2.21M1.524.05 million shs83,747 shsEYEGAB Corporate Bond ETF$35.75+0.1%$1.90$1.44▼$8.18$451.12M0.81935,975 shsN/AKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals-5.00%-22.22%+52.30%-28.49%-85.51%EYEGAB Corporate Bond ETF+0.06%+0.60%+1.50%-0.69%+1,733.31%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$3.17 per shareN/AEYEGAB Corporate Bond ETF$10K45,112.29N/AN/A$1.26 per share28.37KMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00NTECIntec PharmaN/AN/AN/AN/A$16.18 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$12.73M-$5.72N/AN/AN/AN/A-332.86%-212.05%4/4/2024 (Estimated)EYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/ANTECIntec Pharma-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/ALatest NTEC, ADIL, KMPH, and EYEG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A2.152.15EYEGAB Corporate Bond ETF0.013.073.07KMPHZevra Therapeutics0.1410.1010.10NTECIntec PharmaN/A2.342.34OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%EYEGAB Corporate Bond ETF64.16%KMPHZevra Therapeutics19.39%NTECIntec Pharma22.37%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%EYEGAB Corporate Bond ETF58.20%KMPHZevra Therapeutics1.10%NTECIntec Pharma3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals161.66 million1.42 millionNo DataEYEGAB Corporate Bond ETF1412.62 million5.28 millionNot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableNTECIntec Pharma40898,000N/AOptionableNTEC, ADIL, KMPH, and EYEG HeadlinesSourceHeadlineBuy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlookmarkets.businessinsider.com - March 15 at 8:35 AMBuy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 with Promising Developmentsmarkets.businessinsider.com - March 7 at 12:54 AMStocks to Watch Today: RVNL,Glenmark Pharma, PB Fintech,Sula Vineyards and moremsn.com - February 18 at 11:25 PMChhattisgarh education minister calls for expansion of central schools in the statemsn.com - February 2 at 7:53 AMThe 2024 Chicago Titan 100: Here's who made the listdailyherald.com - November 12 at 10:32 AMH.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)markets.businessinsider.com - August 15 at 9:46 AMNGENF - NervGen Pharma Corp.finance.yahoo.com - June 16 at 12:03 AMHow Big Pharma games the system — and keeps drugs prices highpolitico.eu - May 14 at 3:04 PM10-Q: INDAPTUS THERAPEUTICS, INC.marketwatch.com - May 12 at 12:11 AMFibromyalgia Treatment Market Research | 2023-2030marketwatch.com - May 10 at 2:05 AMEarly Pregnancy Test Kit Market May Set Epic Growth Story Major Players – Abbott, Church & Dwight, SPD Swiss Precision Diagnostics GmbHmarketwatch.com - May 9 at 8:55 PMFibromyalgia Treatment Market Share, Size, Financial Summaries Analysis from 2023 to 2028marketwatch.com - May 4 at 7:25 PMFibromyalgia Treatment Market Share by 2031marketwatch.com - April 28 at 12:35 AMIntec Pharma Ltd (5NU.SG)ca.finance.yahoo.com - April 24 at 5:27 PMFibromyalgia Treatment Market Size, Share, Outlook and Forecast to 2031marketwatch.com - March 30 at 9:54 AMMaxim Group Reaffirms Their Buy Rating on Indaptus Therapeutics (INDP)markets.businessinsider.com - March 18 at 10:19 AMFibromyalgia Treatment Market Forecast: An Analysis of Industry Trends for 2023-2028marketwatch.com - March 2 at 7:54 AMPharma in 2023: Growth and Collaborationhealth.economictimes.indiatimes.com - March 1 at 9:53 PMGlobal Parkinson’s Disease Treatment Market Opportunities, Business Statistics Research Report 2030 By VMReportsmarketwatch.com - February 19 at 8:31 AMFibromyalgia Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of Solutionsmarketwatch.com - February 15 at 7:01 PMAaron Rodgers Claims “Big Pharma” Conspired Against Him To Make Him Look Like A “Villain” (VIDEO)totalprosports.com - January 31 at 10:46 PMSyphilis Rapid Test Kit Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2028marketwatch.com - January 30 at 10:56 AMFibromyalgia Treatment Market Industry Updates, New Opportunities, Major Strategies, And Forecast 2028marketwatch.com - January 23 at 11:14 PMIndia says samples taken from pharma firm linked to Gambia deaths meet required standardshealth.economictimes.indiatimes.com - January 13 at 12:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks SoFi Presents Another Entry Opportunity for InvestorsMarch 19, 2024 7:32 AMView SoFi Presents Another Entry Opportunity for InvestorsPaymentus Is a Tech Stock You’re Going To Hear a Lot More AboutMarch 7, 2024 6:05 AMView Paymentus Is a Tech Stock You’re Going To Hear a Lot More AbouteBay Steadily Climbs as Collectors Drive Growth March 25, 2024 6:29 AMView eBay Steadily Climbs as Collectors Drive Growth All Headlines Company DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Zevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Intec PharmaNASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.